Sasanlimab Plus BCG Improves EFS in High-Risk NMIBC
Sasanlimab plus BCG significantly improved EFS vs BCG alone in high-risk non–muscle-invasive bladder cancer.
Related Articles
MAIC Analysis Shows PFS Favorability With Zanubrutinib vs Acalabrutinib/Venetoclax in CLL
A matching-adjusted indirect comparison of zanubrutinib and acalabrutinib/venetoclax showed favorability towards zanubrutinib in patients with CLL.
Isa-KRd Yields Prolonged MRD Negativity vs KRd in Newly Diagnosed Myeloma
Isa-KRd significantly improved the 1-year MRD negativity rate compared with KRd alone in newly diagnosed patients with multiple myeloma.
Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma
Results from dose level G of MagnetisMM-6 found high response rates with an elranatamab triplet in patients with newly diagnosed multiple myeloma.
FDA Grants Orphan Drug Designation to CID-078 for SCLC
The FDA has granted orphan drug designation to CID-078 for the treatment of patients with small cell lung cancer.
Liso-Cel Yields Durable Responses in R/R Marginal Zone Lymphoma
Liso-cel generated deep and durable responses in relapsed/refractory marginal zone lymphoma.
QOL Data Could Help Support Switch to Camizestrant in HR+ Breast Cancer After Emergence of ESR1 Mutation
Hope S. Rugo, MD, breaks down the implications of data from SERENA-6 for the management of emergent ESR1-mutant, HR–positive breast cancer.
Curiosity and Compassion Propel Lung Cancer Pioneer Ramalingam to TIME100 Health 2025 List
Suresh S. Ramalingam, MD, FACP, FASCO, highlights his journey in the lung cancer field, leading up to his recognition on the TIME100 Health 2025 list.
Nominations
Nominations for the 2026 campaign open on Thursday, May 29, 2025. NOMINATE The Giants of Cancer Care ® program, presented by OncLive ®, recognizes and…
Nivolumab Plus Ipilimumab Shows Sustained PFS Benefit in MSI-H/dMMR mCRC
Nivolumab plus ipilimumab displayed superior PFS and PFS2 data vs chemotherapy and nivolumab monotherapy in mismatch repair-deficient colorectal cancer.
Vepdegestrant Improves PFS in ESR1-Mutant ER+/HER2– Advanced Breast Cancer
PFS was improved when patients with ESR1-mutant ER-positive, HER2-negative advanced breast cancer received treatment with vepdegestrant vs fulvestrant.